Clinical Trials

IND-Enabling Studies

Publications

New York Academy of Sciences (NYAS) Symposium on Alzheimer's Disease Therapeutics | December 11, 2018
New York, New York

  • Tau Pathology Reduction with SM07883, A Novel, Potent, and Selective Oral DYRK1A Inhibitor - Potential Therapeutic for Alzheimer’s Disease
    Abstract - Poster

International Conference on Frontotemporal Dementias | November 11 - 14, 2018
Sydney, Australia

  • SM07883, a Novel, Potent, and Selective Oral DYRK1A Inhibitor Reduced Tau Pathology in Preclinical Models
    Abstract - Poster

Clinical Trials on Alzheimer's Disease (CTAD) | October 24 - 27, 2018
Barcelona, Spain

  • SM07883, a novel DYRK1A inhibitor, reduced Tau pathology – discovery and preclinical development of a potential therapeutic for Alzheimer’s disease
    Abstract - Poster

Alzheimer’s Association International Conference (AAIC) | July 22 - 26, 2018
Chicago, IL

  • Tau Pathology Reduction with SM07883, a Novel, Potent, and Selective Oral DYRK1A Inhibitor - a Potential Therapeutic for Alzheimer’s Disease
    Abstract - Slides

Advances in Alzheimer's and Parkinson's Therapies (AAT-AD/PD) Focus Meeting 2018 | March 15 - 18, 2018
Turin, Italy

  • Tau Pathology Reduction with SM07883, a Novel, Potent, and Selective Oral DYRK1A Inhibitor – a Potential Therapeutic for Alzheimer’s Disease
    Abstract - Slides

Royal Society of Medicine's 13th Medical Innovations Summit | September 17, 2016
London, United Kingdom

  • Samumed's Regenerative Medicine Platform
    Slides

Award Winning

Overview: Alzheimer’s Disease

Alzheimer’s Disease (AD) is a chronic neurodegenerative disease affecting an estimated 5.5 million people in the United States (US)1 and over 46 million people worldwide.2

  • It is the most common cause of dementia and currently available therapies treat symptoms, not the disease itself which is ultimately fatal.1 
  • With the world’s aging population, AD is quickly becoming “The Disease of the Century”3, a global epidemic and a socio-economic burden impacting families, social service, and healthcare delivery systems.1

Symptoms of AD generally occur in patients in their mid-60s, though symptoms may occur earlier in patients with familial forms of AD stemming from a genetic predisposition. The disease is initially characterized by progressive memory loss, and then slow progression to severe difficulty in accessing basic brain functions, prompting mental disorders.

Alzheimer’s Disease is a multifactorial disorder that involves several different etiopathological mechanisms ultimately leading to neurodegeneration illustrated at the cellular level by the presence of neurofibrillary tangles composed of the hyper-phosphorylated forms of the protein tau and insoluble β-amyloid plaques.

References

    1. Alzheimer’s Association. 2016 Alzheimer’s Disease Facts and Figures. Alzheimers Dement. 2016;12(4).
    2. Alzheimer’s Disease International. World Alzheimer’s Report 2015: The Global Impact of Dementia.http://www.alz.co.uk/research/WorldAlzheimerReport2015.pdf. Accessed 10/22/2016.
    3. Simpson SL. Alzheimer’s: The Disease of the Century. LinkedIn article. Website: https://www.linkedin.com/pulse/alzheimers-disease-century-shelby-l-simpson-basw. Accessed 10/22/16.